Practical Guide to the EMA’s Draft EU GMP Revisions

REPHINE SPEECH MARKS OPEN DIGITALISATION.png

Is your organisation truly prepared for the EMA’s upcoming EU GMP revisions?
REPHINE SPEECH MARKS CLOSE DIGITALISATION.png

About this Whitepaper

A profound shift is taking place across the pharmaceutical and biotech sector as the EMA introduces major draft revisions to EU GMP. The updates to Chapter 4, Annex 11 and the brand‑new Annex 22 redefine expectations for documentation, computerised systems and the responsible use of AI in regulated environments. These changes mark a move towards fully digital, data‑driven quality systems where integrity, traceability and lifecycle governance take centre stage.

 

What’s changing?

  • Documentation now spans hybrid, electronic and multimedia formats, requiring stronger control, metadata management and secure retention processes.
  • Computerised systems face heightened expectations around validation, cybersecurity, supplier oversight and lifecycle governance.
  • Annex 22 introduces the first formal GMP framework for AI, demanding clear intended use, robust model validation and mandatory human oversight.
  • Data integrity principles (ALCOA++) now extend across all systems and formats, reinforcing the need for traceable, secure and reliable information.
  • Organisations must strengthen cross‑functional collaboration between Quality, IT, Manufacturing and Data Science to meet the new requirements.

 

Why it matters for your business

This updated regulatory landscape raises both the bar and the opportunity. Companies must:

  • Map and reassess documentation practices across all digital and hybrid records.
  • Ensure computerised systems remain compliant throughout their lifecycle, not just at validation.
  • Review cloud, SaaS and supplier relationships to align with stricter expectations.
  • Establish or reinforce AI governance frameworks before adoption accelerates.
  • Build audit readiness through transparent, well‑controlled data flows and cross‑functional accountability.

These revisions are tightly connected to quality management, data governance and digital maturity—impacting operational efficiency, inspection readiness and competitive positioning.

 

Take action now

With final publication expected in 2026, organisations should begin preparing immediately. Updating procedures, conducting gap assessments, enhancing validation strategies and strengthening AI oversight will be essential steps to ensure compliance and unlock the benefits of a modern, digital‑first quality system.
 

👉 Our full white paper provides clear guidance, practical recommendations and expert insights to help you navigate and implement the upcoming EMA GMP revisions with confidence.

 

Download the White Paper below

WP CSV EMAs Revisions scaled.png

View our other resources and company news

mock inspection blog header Case Study

Full GMP Internal Audit Program Executed On Time

A pharmaceutical manufacturer needed to complete their annual EU GMP internal audit cycle across 11 departments, without the internal capacity to do it. See how ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan QMS

From local to global: scaling your QMS for UK–EU operations

Learn how UK life sciences companies can scale their quality management system into EU markets without losing compliance, visibility, or operational control.
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan QMS

Scale Your Quality System from UK to EU Without Losing Control

Learn how UK life sciences companies can scale their quality management system into EU markets without losing compliance, visibility, or operational control.
Read More
SAP PALEX CSV Case Study Header Image (1500 x 844 px) Article

Pharmaceutical Equipment Qualification & Control System Validation

Qualifying process equipment and control systems is fundamental to GMP compliance. This guide breaks down how to define user requirements, apply risk-based testing, and maintain ...
Read More
mock inspection blog header Case Study

GMP Consultancy for a New Cannabis Manufacturing Plant

A start up cannabis manufacturer partnered with Rephine to design a GMP compliant facility, implement a practical Quality Management System and prepare for EU GMP ...
Read More
QMS IMP Header image case study May 25 Article

How an Internal Services Audit Can Maximise Your Regulatory Compliance

Internal services audits play a critical role in maintaining GMP compliance and driving continuous improvement. This article explores how structured gap assessments, internal audits and ...
Read More
GMP Raising the bar Blog series Header image May 25 Article

Effective QMS Management Post-Go-Live: Strategies for Governance, Releases, and Continuous Improvement

After QMS go live, compliance and performance depend on strong governance, structured release management and continuous improvement. Learn how to sustain control, adoption and long ...
Read More
Ensuring Compliance and Data Integrity in Pharmacovigilan Case Study

GMP Consultancy for a New Manufacturing Plant

With only a small team and a highly automated process, this biotech company needed to achieve EU GMP compliance fast. This case study shows how ...
Read More
ICH E6 Guide Header Image (1500 x 844 px) Article

Why Quality Can No Longer Live in Silos

Discover why siloed quality management is no longer sustainable in life sciences. Learn how integrating audits, advisory services and digital quality systems supports continuous GxP ...
Read More
Contact Us

Strengthen Your Assurance Journey

GMP Chapter 22 Adapting to Hybrid Documentation Standards